
CSL Ltd’s (ASX: CSL) board has admitted the financial performance of the business has been disappointing, but vowed to do better ahead of the company’s upcoming annual general meeting.
Aiming for improvement
In the notice of meeting lodged with the ASX, CSL chair Brian McNamee said the past year had been one of “significant change” for the blood products company, “and the board acknowledges that many shareholders are frustrated with the recent disappointing commercial and financial performance of the company”.
Mr McNamee added:
This includes reporting a multibillion-dollar statutory loss, driven by significant restructuring activity, leadership transition and the recognition of substantial non-cash balance sheet impairments. We built up substantial fixed costs, we were slow to adapt to competitive pressures, our research and development efforts didn’t deliver and some investments the Company made did not perform. We recognise this, and the management team is acting with urgency to earn back the confidence of shareholders through results.
Mr McNamee said the company’s core markets remained attractive, and the business was resilient and delivering strong cash flows.
He said the strategy was to invest in the core of the plasma business, “with selective investment beyond that”.
He added:
The industry fundamentals remain attractive. Plasma is a structurally stable therapeutic area, with durable demand and significant unmet patient need. CSL also maintains strength in influenza vaccines through the Seqirus business.
Mr McNamee said the board was encouraged by the early positive results of changes implemented by the management team.
He said the company needed to focus on stronger execution and adapt more rapidly as markets evolve.
Mr McNamee said the search for a new Chief Executive Officer was well-advanced, and in the meantime interim CEO Gordon Naylor was positioning the company for the next phase of growth.
CSL shares were 1 cent lower at $174.40 on Thursday. The shares have traded as low as $90 over the past year and as high as $222.47.
CSL shares looking like a good buy
Brokers are currently positive on the outlook for CSL following the company’s August results release.
RBC Capital Markets this week upgraded the company to an outperform rating with a $213 price target.
The broker said they now believed that “growth in the Behring business can offset the weak outlook in the Seqirus and Vifor business, and enable the company to deliver mid-single digit EPS growth for the next 3 years”.
The company is valued at $83.7 billion. The AGM will be held on Tuesday 27 October.
The post CSL acknowledges “disappointing” results but aims to do better appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right nowâ¦
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded
- Two broker upgrades put CSL shares back in focus
- Is the CSL share price heading to $200?
- CSL shares have surged over 25%. Do brokers see more upside?
- CSL shares just fell 5% after a strong rally. Is the recovery losing steam?
Motley Fool contributor Cameron England has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

